Chronic traumatic encephalopathy neuropathologic change is associated with highest stage limbic-predominant age-related TDP-43 encephalopathy
Journal of Neuropathology & Experimental Neurology · 27.04.2026
DOI: 10.1093/jnen/nlag040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, online erschienen am 27.04.2026. Verfasst von Hailong Song und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Center for Brain Injury and Repair, University of Pennsylvania, Philadelphia, PA, United States. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Association, NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Traumatic brain injury (TBI) is recognized as a major risk factor for neurodegenerative disease (NDD). Autopsy studies frequently describe chronic traumatic encephalopathy neuropathologic change (CTE-NC) in individuals with histories of repetitive head impact (RHI) exposure, often with accompanying comorbid neurodegenerative proteinopathies. Of these, deposition of abnormally phosphorylated TDP-43 (pTDP-43) has been reported but the prevalence and distribution of pTDP-43 in CTE-NC and its distinction from that encountered in wider NDD are uncertain. Here, patients with a history of RHI and documented NDD (n = 30), and age-matched controls with no known TBI or RHI exposure, either with (n = 24) or without (n = 18) NDD, were identified within the CONNECT-TBI archive. Standardized brain tissue sections stained for pTDP-43 were assessed. pTDP-43 pathology prevalence was similar among RHI patients (40%) and controls with NDD (33%). pTDP-43 was typically localized (limbic-predominant age-related TDP-43 encephalopathy neuropathologic change [LATE-NC] stage 1 to 2) in amygdala and hippocampus in controls with NDD and following RHI exposure without CTE-NC. In contrast, this pathology was often widespread and of high stage (LATE-NC stage 3; P = .0045) in patients with CTE-NC. Thus, CTE-NC may be associated with more widespread pTDP-43 pathology than encountered in aging or those with NDD and no history of TBI/RHI.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Center for Brain Injury and Repair, University of Pennsylvania, Philadelphia, PA, United States.
- School of Health and Life Sciences, Teesside University, Middlesbrough, United Kingdom.
- School of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
- Translational Neuropathology Research Laboratory, University of Pennsylvania, Philadelphia, PA, United States.
- Department of Neuropathology, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
ORCID-Profile: William Stewart
Förderung
- Alzheimer's Association
- NIH HHS
- NINDS NIH HHS
- Medical Research Council
- NIA NIH HHS
- NHS Research Scotland
- National Institutes of Health
- Alzheimer’s Association
Zitieren
APA
Song, H., Ameen-Ali, K. E., Kennedy-Dietrich, C., Dolle, J. P., Lee, E. B., Smith, D. H., Stewart, W., & CONNECT-TBI Investigators (2026). Chronic traumatic encephalopathy neuropathologic change is associated with highest stage limbic-predominant age-related TDP-43 encephalopathy. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlag040
Vancouver
Song H, Ameen-Ali KE, Kennedy-Dietrich C, Dolle JP, Lee EB, Smith DH, et al. Chronic traumatic encephalopathy neuropathologic change is associated with highest stage limbic-predominant age-related TDP-43 encephalopathy. Journal of Neuropathology & Experimental Neurology. 2026. doi:10.1093/jnen/nlag040
BibTeX
@article{Song2026,
author = {Song, Hailong and Ameen-Ali, Kamar E and Kennedy-Dietrich, Claire and Dolle, Jean-Pierre and Lee, Edward B and Smith, Douglas H and Stewart, William and CONNECT-TBI Investigators, CONNECT-TBI Investigators},
title = {Chronic traumatic encephalopathy neuropathologic change is associated with highest stage limbic-predominant age-related TDP-43 encephalopathy},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2026},
doi = {10.1093/jnen/nlag040}
}
EUVIMED